TerrAscend (TSNDF) Gains from Investment Securities (2021 - 2025)
TerrAscend's (TSNDF) quarterly Gains from Investment Securities came in at -$179000.0 in Q4 2025, up 83.46% year-on-year from -$97570.8 in Q4 2024, and up 84.71% on a QoQ basis from -$1.2 million in Q3 2025.
TerrAscend (TSNDF) Gains from Investment Securities (2021 - 2025) Analysis & Trends
TerrAscend (TSNDF) has 5 years of Gains from Investment Securities data on file, last reported at -$179000.0 in Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 83.46% year-over-year to -$179000.0 in Q4 2025; TTM through Mar 2026 was -$1.4 million, a 195.25% decrease from a year earlier, with the FY2025 full-year figure at -$1.0 million, down 140.73% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$179000.0, up from -$1.2 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for TSNDF reached as high as $3.0 million in Q1 2021 and fell as low as -$1.2 million in Q4 2022.
- Historically, Gains from Investment Securities has averaged $196470.6 across 5 years, with a median of $34000.0 in 2022.
- Across the five-year window, Gains from Investment Securities jumped 585.71% in 2022 and tumbled 1891.67% in 2023, its largest moves.
- Year by year, Gains from Investment Securities stood at $932000.0 in 2021, then tumbled by 234.12% to -$1.2 million in 2022, then surged by 48.4% to -$645000.0 in 2023, then sank by 67.75% to -$1.1 million in 2024, then surged by 83.46% to -$179000.0 in 2025.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$179000.0 in Q4 2025, -$1.2 million in Q3 2025, and -$34000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | TerrAscend | 158.89 Mn | 158.42 Mn | 34.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -179,000.00 |
| Dec 31, 2025 | -179,000.00 |
| Sep 30, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.17 Mn |
| Jun 30, 2025 | -34,000.00 |
| Jun 30, 2025 | -34,000.00 |
| Mar 31, 2025 | 381,000.00 |
| Mar 31, 2025 | 381,000.00 |
| Dec 31, 2024 | -1.08 Mn |
| Dec 31, 2024 | -1.08 Mn |
| Sep 30, 2024 | 327,000.00 |
| Sep 30, 2024 | 327,000.00 |
| Jun 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Sep 30, 2023 | -645,000.00 |
| Sep 30, 2023 | -645,000.00 |
| Dec 31, 2022 | -1.25 Mn |
| Dec 31, 2022 | -1.25 Mn |